Enoblituzumab (Anti-B7-H3 / CD276)
Enoblituzumab (Anti-B7-H3 / CD276) (A2626-GRP)
Products
Description
Enoblituzumab (Anti-B7-H3 / CD276) is a humanized IgG1κ monoclonal antibody targeting human B7-H3 protein. It can be used in the treatment of medullary thyroid cancer (MTC). MW :150 KD.
Specifications
| Manufacturer | Selleck Chemicals LLC |
|---|---|
| Manufacturer Cat# | A2626 |
| Target | CD markers |